Profile data is unavailable for this security.
About the company
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
- Revenue in USD (TTM)681.75m
- Net income in USD70.47m
- Incorporated2006
- Employees711.00
- LocationPacira Biosciences Inc5401 West Kennedy Boulevard, Suite 890TAMPA 33609United StatesUSA
- Phone+1 (813) 553-6680
- Fax+1 (302) 655-5049
- Websitehttps://www.pacira.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vir Biotechnology Inc | 79.60m | -539.44m | 1.32bn | 587.00 | -- | 0.8542 | -- | 16.63 | -4.01 | -4.01 | 0.5916 | 11.39 | 0.0357 | -- | -- | 135,603.10 | -24.19 | -0.6081 | -27.80 | -0.7192 | 98.85 | -- | -677.69 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
Cullinan Therapeutics Inc | 0.00 | -153.16m | 1.34bn | 85.00 | -- | 2.19 | -- | -- | -3.70 | -3.70 | 0.00 | 10.58 | 0.00 | -- | -- | 0.00 | -29.68 | -12.37 | -31.19 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
Belite Bio Inc (ADR) | 0.00 | -32.61m | 1.37bn | 20.00 | -- | 13.89 | -- | -- | -1.18 | -1.18 | 0.00 | 3.24 | 0.00 | -- | -- | 0.00 | -46.26 | -- | -46.26 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
Akero Therapeutics Inc | 0.00 | -179.27m | 1.38bn | 58.00 | -- | 1.63 | -- | -- | -3.20 | -3.20 | 0.00 | 12.24 | 0.00 | -- | -- | 0.00 | -28.43 | -37.73 | -29.53 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0395 | -- | -- | -- | -35.46 | -- | -- | -- |
Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.40bn | 297.00 | 232.04 | 3.24 | 129.13 | 4.65 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
Day One Biopharmaceuticals Inc | 0.00 | -208.94m | 1.41bn | 174.00 | -- | 4.76 | -- | -- | -2.50 | -2.50 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -64.27 | -- | -69.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
Xencor Inc | 162.18m | -133.36m | 1.42bn | 280.00 | -- | 2.32 | -- | 8.76 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
Pacira Biosciences Inc | 681.75m | 70.47m | 1.43bn | 711.00 | 23.78 | 1.61 | 9.90 | 2.10 | 1.30 | 1.30 | 12.11 | 19.18 | 0.4389 | 1.93 | 7.00 | 958,866.40 | 4.54 | 3.35 | 4.84 | 3.98 | 73.15 | 72.63 | 10.34 | 8.57 | 4.78 | 51.11 | 0.3684 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
Tarsus Pharmaceuticals Inc | 42.56m | -148.21m | 1.44bn | 244.00 | -- | 5.25 | -- | 33.95 | -4.72 | -4.72 | 1.35 | 7.29 | 0.1519 | -- | 2.63 | 174,430.30 | -52.88 | -31.56 | -58.73 | -33.82 | 92.37 | -- | -348.22 | -242.59 | 7.92 | -- | 0.0981 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
Dynavax Technologies Corp | 236.15m | 9.22m | 1.45bn | 408.00 | 222.42 | 2.35 | 106.34 | 6.16 | 0.05 | 0.05 | 1.67 | 4.73 | 0.2414 | 0.7769 | 3.24 | 578,796.60 | 0.9427 | 4.16 | 1.02 | 5.71 | 80.34 | 64.83 | 3.91 | 9.19 | 14.10 | -- | 0.265 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
Morphic Holding Inc | 0.00 | -161.25m | 1.46bn | 124.00 | -- | 2.21 | -- | -- | -3.49 | -3.49 | 0.00 | 13.25 | 0.00 | -- | -- | 0.00 | -28.67 | -22.69 | -29.49 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
Avadel Pharmaceuticals PLC (ADR) | 55.14m | -156.83m | 1.49bn | 154.00 | -- | 18.99 | -- | 27.00 | -1.86 | -1.86 | 0.6334 | 0.8157 | 0.3573 | -- | 4.80 | 358,058.40 | -101.63 | -40.21 | -172.85 | -47.99 | 95.71 | -- | -284.42 | -374.75 | 2.60 | -14.71 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
Spyre Therapeutics Inc | 688.00k | -364.23m | 1.52bn | 30.00 | -- | -- | -- | 2,213.25 | -71.35 | -71.35 | 0.0456 | 11.08 | 0.0026 | -- | -- | 22,933.33 | -134.88 | -101.87 | -150.32 | -118.83 | -- | -- | -52,939.68 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
Arcus Biosciences Inc | 237.00m | -231.00m | 1.54bn | 577.00 | -- | 2.17 | -- | 6.49 | -3.10 | -3.10 | 3.07 | 7.78 | 0.1861 | -- | 6.24 | 410,745.20 | -18.14 | -15.85 | -21.35 | -18.25 | -- | -- | -97.47 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
Neumora Therapeutics Inc | 0.00 | -254.02m | 1.54bn | 120.00 | -- | 3.63 | -- | -- | -2.44 | -2.44 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
Ligand Pharmaceuticals Inc | 118.31m | 96.34m | 1.55bn | 58.00 | 16.44 | 1.91 | 11.70 | 13.07 | 5.23 | 5.23 | 6.52 | 45.00 | 0.1372 | 0.5475 | 4.11 | 2,039,879.00 | 11.17 | 12.32 | 11.98 | 12.99 | 91.82 | 81.65 | 81.43 | 80.32 | 19.51 | -- | 0.00 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 7.10m | 15.26% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 4.98m | 10.72% |
Frontier Capital Management Co. LLCas of 31 Dec 2023 | 2.08m | 4.48% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.94m | 4.16% |
Renaissance Technologies LLCas of 31 Dec 2023 | 1.72m | 3.69% |
Dimensional Fund Advisors LPas of 31 Mar 2024 | 1.63m | 3.50% |
Pacer Advisors, Inc.as of 31 Mar 2024 | 1.57m | 3.38% |
Macquarie Investment Management Business Trustas of 31 Dec 2023 | 1.38m | 2.98% |
Stephens Investment Management Group LLCas of 31 Dec 2023 | 1.33m | 2.86% |
Vestal Point Capital LPas of 31 Dec 2023 | 1.20m | 2.58% |